Last reviewed · How we verify
OBR
OBR is a long-acting injectable antipsychotic that blocks dopamine D2 receptors in the brain to treat schizophrenia and bipolar disorder.
OBR is a long-acting injectable antipsychotic that blocks dopamine D2 receptors in the brain to treat schizophrenia and bipolar disorder. Used for Schizophrenia (maintenance treatment), Bipolar I disorder (maintenance treatment).
At a glance
| Generic name | OBR |
|---|---|
| Sponsor | Otsuka Pharmaceutical Development & Commercialization, Inc. |
| Drug class | Atypical antipsychotic (depot formulation) |
| Target | Dopamine D2 receptor (partial agonist) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
OBR (aripiprazole monohydrate) is a depot formulation of aripiprazole, a partial dopamine D2 receptor agonist. It is administered as a monthly intramuscular injection, providing sustained antipsychotic effects by maintaining therapeutic dopamine antagonism over an extended period, thereby improving medication adherence and reducing relapse rates in psychotic disorders.
Approved indications
- Schizophrenia (maintenance treatment)
- Bipolar I disorder (maintenance treatment)
Common side effects
- Injection site pain
- Akathisia
- Headache
- Tremor
- Weight gain
Key clinical trials
- Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis (PHASE1)
- Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance (PHASE2, PHASE3)
- A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults (PHASE3)
- Comparison of Cardiometabolic Markers in Individuals With Hypertriglyceridemia With Low and High Weight Loss Responses to an Energy-restricted Diet (NA)
- Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice
- Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children (PHASE2)
- Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy (PHASE2)
- A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OBR CI brief — competitive landscape report
- OBR updates RSS · CI watch RSS
- Otsuka Pharmaceutical Development & Commercialization, Inc. portfolio CI